Home › application
 

Keywords :   


Tag: application

Disability Leadership Academy Application form - PDF version

2016-12-07 04:04:20| PortlandOnline

Application form for the Disability Leadership Academy in a PDF document. PDF Document, 373kbCategory: Disability Leadership Academy

Tags: version form pdf application

 

Application for Membership

2016-12-02 22:33:46| PortlandOnline

PDF Document, 96kbCategory: About Us

Tags: application membership

 
 

Top 5 stories: Court approval given to seed treatments and the pitfalls to in-furrow fertilizer application

2016-12-02 19:28:00| Corn & Soybean Digest

In this week's top 5 ag stories, we take a look at a court ruling out of California regarding seed treatments and the credit concerns regarding the ag community. read more

Tags: to top application stories

 

Teen Job Application - New Applicants

2016-12-01 22:32:17| PortlandOnline

YCC job application for youth ages 14-18 PDF Document, 2,138kbCategory: Youth Conservation Crew

Tags: application job teen applicants

 

FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Mercks KEYTRUDA (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma

2016-12-01 13:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or for patients who have relapsed after three or more prior lines of therapy. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: review application license classical

 

Sites : [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] next »